Obesity Drug Comparison: What a Major BMJ Study Found

Important note: This article is for general education only. It is not medical advice. Obesity medications can have benefits, risks, side effects, contraindications, and coverage limitations. Do not start, stop, switch, or compare medications based on this article alone. Talk with your doctor, pharmacist, or another qualified healthcare professional about which treatment options, if any, are appropriate for you.

A major new analysis in The BMJ compared 19 medications used or being studied for adults with overweight or obesity.

The study reviewed 262 randomized controlled trials involving 99,791 participants. It looked at more than weight loss. Researchers also compared side effects, treatment discontinuation, cardiovascular outcomes, kidney outcomes, lean mass, quality of life, and what happens after treatment stops.

The findings confirm something many people already know: newer obesity medications can produce meaningful weight loss.

But the study also makes something else clear: the “best” medication is not the same for every person.

Some drugs produced more weight loss. Some had stronger cardiovascular evidence. Some were linked with more side effects or higher discontinuation rates. Some had limited evidence for outcomes patients may care about most, such as quality of life, strength, long-term function, and what happens after stopping.

That is why this study matters. It moves the conversation beyond “which drug causes the most weight loss?” and toward a more useful question: which treatment profile fits which patient?

What kind of study was this?

The BMJ paper was a systematic review and network meta-analysis.

A systematic review gathers and evaluates existing studies using a structured method. A network meta-analysis goes one step further. It can compare treatments even when they have not all been tested directly against each other in the same head-to-head trial.

That is helpful in a fast-moving field like obesity medicine, where medications may be studied in different trials, populations, doses, and time periods.

But it also has limits. A network meta-analysis is only as strong as the studies it includes. If some outcomes were not measured often, if trials were short, or if the patient groups differed, the comparison becomes less certain.

So this study is useful, but it is not a simple ranking chart for individual patients.

Which medications produced the most weight loss?

At one year, the largest average body-weight reductions were seen with newer incretin-based medications.

Compared with lifestyle changes alone, BMJ’s summary reported the greatest one-year weight loss with tirzepatide at 14.9% and CagriSema at 14.8%. Oral semaglutide followed at 10.9%, orforglipron at 9.9%, subcutaneous semaglutide at 9.8%, and phentermine-topiramate at 8.1%.

Those numbers are meaningful, but they need context.

CagriSema, retatrutide, ecnoglutide, mazdutide, and some other medications included in the analysis may be investigational, not approved for routine use, or not available in every country. BMJ also noted that emerging medications such as retatrutide, ecnoglutide, and mazdutide showed large effects on weight loss, but were supported by low or very low certainty evidence.

That means patients should not treat every medication in the analysis as an available option.

A drug can look promising in research and still be unavailable, unapproved, not covered by insurance, or not appropriate for a specific person.

Weight loss is not the only outcome

The BMJ study is especially useful because it did not only ask, “Which medication causes the most weight loss?”

It also looked at broader outcomes, including mortality, heart attacks, heart failure, kidney failure, lean mass, side effects, treatment discontinuation, and quality of life.

That wider view matters because many people do not take obesity medications only to see a number change on the scale. They may be hoping for better mobility, lower cardiometabolic risk, fewer symptoms, improved energy, or better long-term health.

The study found that subcutaneous semaglutide currently has the strongest evidence for reductions in mortality and major cardiovascular outcomes.

But that does not mean every person taking semaglutide will have those outcomes. Cardiovascular evidence often comes from specific trial populations, such as people with established heart disease or higher baseline risk. Expert commentary on the BMJ study emphasized that these findings need nuance because many obesity trials were not long enough or specifically designed to measure outcomes such as heart attacks, mortality, or kidney failure.

The practical takeaway is not “one drug is best.” It is that different medications may have different evidence profiles.

What did the study say about quality of life?

One of the more sobering findings was that most obesity medications did not show quality-of-life improvements that crossed the threshold researchers considered clinically meaningful.

That does not mean people never feel better on these medications. Many people report meaningful personal changes, such as less food noise, easier movement, improved labs, or feeling more in control of routines.

But quality of life is complicated. It can be affected by side effects, cost, access stress, stigma, muscle loss, fatigue, gastrointestinal symptoms, social changes, and the burden of long-term treatment.

The BMJ finding is a reminder that weight loss alone does not capture the whole patient experience.

A treatment may reduce weight and still require support around food, hydration, movement, side effects, mood, body image, and long-term planning.

Lean mass is part of the picture

The study also looked at body composition.

BMJ’s summary reported that tirzepatide reduced fat mass the most, but it also reduced lean mass the most among the drugs analyzed.

Lean mass includes muscle, water, organs, bone, and other non-fat tissue. Muscle is only one part of lean mass, but it is the part many patients worry about because it supports strength, balance, mobility, and daily function.

This does not mean tirzepatide or other GLP-1-related medications are “bad for muscle.” It means significant weight loss can include lean tissue loss, and body composition deserves attention.

For patients, that may mean asking a care team about protein, resistance training, strength, hydration, and whether symptoms like weakness, dizziness, fatigue, or loss of stamina should be evaluated.

More weight loss can come with more trade-offs

The BMJ authors concluded that larger weight-loss benefits were generally accompanied by greater harms, treatment burden, and discontinuation.

That is important because medication choice is not only about the strongest average result.

A medication that produces more weight loss may also cause more nausea, vomiting, diarrhea, constipation, fatigue, or treatment interruptions. Some people may tolerate a medication well. Others may not.

The best treatment for one person may not be the medication with the highest average weight-loss number. It may be the medication that fits their health history, side effect risk, treatment goals, daily routine, coverage, and ability to follow up with a care team.

That is why obesity medication decisions should be individualized.

Why stopping matters

The BMJ analysis also emphasized that improvements are generally not sustained after treatment stops.

That finding is consistent with other research showing that weight regain can occur after stopping obesity medications. It does not mean someone should continue medication indefinitely without question. It means stopping, pausing, switching, or restarting should be discussed with a healthcare professional.

For patients, this is one of the most important practical questions to ask before starting:

What is the long-term plan?

That plan may include medication, nutrition support, strength training, follow-up visits, side effect management, maintenance planning, coverage planning, or a strategy for what to do if access changes.

How patients can use this information

This study should not be used as a do-it-yourself medication ranking.

Instead, it can help patients ask better questions.

You might ask your doctor or pharmacist:

Which medications are actually approved for my condition?

Which options fit my health history?

What side effects are most common with this medication?

How should we think about lean mass, protein, and strength?

What benefits beyond weight loss are supported by evidence for someone like me?

What outcomes should we track?

What happens if I cannot tolerate the medication?

What happens if insurance coverage changes?

What is the long-term plan if I start?

Those questions are more useful than trying to pick a medication based only on a percentage from a study.

Where Glo fits in

Glo is designed to support the everyday space between appointments.

For people using doctor-prescribed GLP-1 and GLP-1-related medications, Glo can help track meals, hydration, movement, side effects, symptoms, routines, reminders, and habits by text. It can also help people organize questions for a doctor, pharmacist, dietitian, or other care team member.

That kind of support matters because the BMJ study shows how much happens beyond the scale.

Side effects matter. Strength matters. Consistency matters. Daily routines matter. Long-term planning matters.

Glo does not compare medications for individual patients. It does not recommend one medication over another. It does not replace medical care.

But it can help people notice patterns and bring clearer information to the care team making those decisions.

Bottom line

The BMJ analysis is one of the most comprehensive comparisons so far of obesity medications.

It found that tirzepatide and CagriSema produced the greatest average weight loss among the drugs analyzed, while subcutaneous semaglutide currently has the strongest evidence for reductions in mortality and major cardiovascular outcomes. It also found important trade-offs, including side effects, discontinuation, lean mass loss, and limited evidence for clinically meaningful quality-of-life improvements.

The message is not that one medication wins.

The message is that obesity treatment is becoming more individualized.

For patients, the right question is not “Which drug ranked first?” It is “Which option is safest, most appropriate, most tolerable, and most sustainable for me?”

That answer belongs in a conversation with a qualified healthcare professional, not in a headline.